联系客服QQ:86259698

300147 深市 香雪制药


首页 公告 ST香雪:2024年度财务决算报告

ST香雪:2024年度财务决算报告

公告日期:2025-04-29


                    广州市香雪制药股份有限公司

                      2024 年度财务决算报告

        广州市香雪制药股份有限公司(以下简称“公司”)2024年度财务报表经北京

    德皓国际会计师事务所(特殊普通合伙)审计,审计意见为标准无保留。现将2024

    年度财务决算报告如下(均为合并数据):

        一、主要财务指标

        2024 年,公司实现营业收入 185,866.21 万元,同比下降 19.16%;利润总额

    -84,207.06 万元,同比下降 116.5%;归属于母公司股东的净利润-85,856.00 万元,

    同比下降 120.73%。主要财务数据如下:

                          2024 年              2023 年          本年比上年增减          2022 年

营业收入(元)          1,858,662,132.42    2,299,287,682.53              -19.16%    2,187,069,901.40

归属于上市公司股东      -858,559,973.29      -388,963,842.58            -120.73%      -530,057,977.84
的净利润(元)
归属于上市公司股东

的扣除非经常性损益      -819,205,274.18      -344,457,186.87            -137.82%      -550,008,234.88
的净利润(元)

经营活动产生的现金        18,174,822.85      263,441,902.31              -93.10%      227,377,262.86
流量净额(元)

基本每股收益(元/股)                -1.3                -0.59            -120.34%                -0.80

稀释每股收益(元/股)                -1.3                -0.59            -120.34%                -0.80

加权平均净资产收益              -57.41%              -18.35%              -39.06%              -20.68%


                          2024 年末            2023 年末        本年末比上年末增减        2022 年末

资产总额(元)          7,498,398,859.64    8,280,629,979.39              -9.45%    8,642,021,051.82

归属于上市公司股东    1,054,899,213.92    1,924,701,823.57              -45.19%    2,306,779,629.74
的净资产(元)

        二、主营业务收入构成

                                                                          单位:元

                              2024 年                            2023 年                  同比增减

                      金额        占营业收入比重        金额        占营业收入比重

营业收入合计      1,858,662,132.4            100%  2,299,287,682.5            100%          -19.16%
                                2                                  3

分行业

医药制造          302,701,919.89          16.29%  825,287,862.09          35.89%          -63.32%

医药流通          252,403,774.97          13.58%  360,355,852.49          15.67%          -29.96%

医疗器械            20,085,095.86            1.08%    17,418,614.66            0.76%          15.31%

其它              347,367,274.87          18.69%  351,472,648.99          15.29%          -1.17%

中药材            936,104,066.83          50.36%  744,752,704.30          32.39%          25.69%

分产品


抗病毒口服液        83,697,335.03            4.50%  430,096,337.89          18.71%          -80.54%

橘红系列          107,902,762.39            5.81%  216,937,946.03            9.44%          -50.26%

其他              730,957,968.17          39.33%  907,500,694.31          39.47%          -19.45%

中药材            936,104,066.83          50.36%  744,752,704.30          32.39%          25.69%

分地区

广东省            413,141,362.90          22.23%  737,276,305.01          32.07%          -43.96%

西南区              71,819,498.30            3.86%  110,025,249.84            4.79%          -34.72%

华中区              99,950,954.05            5.38%  219,375,280.20            9.54%          -54.44%

华北、华东及东北  1,273,750,317.1          68.53%  1,232,610,847.4          53.61%            3.34%
区                              7                                  8

分销售模式

直营销售模式      1,661,527,991.0          89.39%  1,763,697,824.5          76.71%          -5.79%
                                9                                  0

经销模式          197,134,141.33          10.61%  535,589,858.03          23.29%          -63.19%

        三、2024 年末资产负债变动情况

                                                                          单位:元

                        2024 年末                      2024 年初              比重增减    重大变动说明
                  金额      占总资产比例      金额      占总资产比例

货币资金        131,741,496.          1.76%  149,316,999.          1.80%        -0.04%

                          06                            85

应收账款        810,129,690.        10.80%  704,939,229.          8.51%          2.29%

                          20                            85

合同资产                              0.00%                        0.00%          0.00%

存货            340,919,525.          4.55%  411,297,654.          4.97%        -0.42%

                          62                            94

投资性房地产            0.00          0.00%          0.00          0.00%          0.00%

长期股权投资    33,063,032.9          0.44%  43,706,227.8          0.53%        -0.09%

                          8                            4

固定资产        3,613,994,04        48.20%  3,369,354,40        40.69%          7.51%  本报告期在建
                        7.18                          0.44                                工程转固所致

在建工程        614,627,351.          8.20%  1,214,429,17        14.67%        -6.47%  本报告期在建
                          41                          7.78                                工程转固所致

使用权资产      30,677,515.2          0.41%  36,163,278.0          0.44%        -0.03%

                          8                            5

短期借款        1,355,145,83        18.07%  1,498,076,78